Substance and claimed effects

Uterine fibroids (leiomyomas, myomas) are benign monoclonal tumors of uterine smooth muscle, the most common pelvic neoplasm in people with a uterus. Ultrasound-based screening puts cumulative incidence by age 50 at ~70% in white women and >80% in Black women (Baird et al. 2003), with prevalence estimates spanning 4.5–68.6% depending on population and ascertainment method (Stewart et al. 2017). Approximately 25% of women with fibroids develop symptoms severe enough to warrant treatment; the dominant phenotypes are heavy menstrual bleeding (HMB) with secondary iron-deficiency anemia, bulk/pressure symptoms (urinary frequency, constipation, dyspareunia, abdominal distention), and reproductive/obstetric morbidity (ACOG 2021). Consequences this entry covers holistically: short-term health (HMB/anemia, pelvic pressure, pain), mood (psychological burden of HMB and chronic anemia), beauty (visible abdominal distention with bulky disease; anemia-driven pallor), fertility and pregnancy outcomes, longevity (very modest — fibroids are not lethal but morcellation of an occult sarcoma is), and the high cost/effort burden of definitive treatment. The article is anchored on location-stratified management (FIGO 0–8), because the same diagnosis produces very different clinical pictures and treatment menus depending on where the fibroid sits.

Evidence by addressing question

mechanism

Cellular origin and hormonal dependency. Each fibroid is a clonal expansion from a single myometrial smooth-muscle precursor, driven by ovarian steroids. Estradiol primes the tissue and upregulates progesterone receptors; progesterone — acting through PR on mature fibroid cells — is the dominant proliferative signal, working partly through paracrine release of WNT ligands, RANKL, EGF, and TGF-β3 onto adjacent stem cells (Bulun et al. 2024). Both the mutated myocytes and tumor-associated fibroblasts lay down excessive extracellular matrix, which is why these tumors are firm and disproportionately heavy for their cellular content.

Genetic drivers. Somatic gain-of-function mutations in MED12 (a subunit of the Mediator transcriptional co-activator complex) are present in 50–80% of fibroids and are the single most common driver lesion. HMGA2 rearrangements account for another ~10%, and germline FH mutations underlie hereditary leiomyomatosis and renal cell carcinoma (HLRCC) (Bulun et al. 2024). MED12-mutant tumors disrupt CDK8/19 kinase activity in the Mediator complex, dysregulate Wnt/β-catenin signaling, and show heightened progesterone responsiveness — likely explaining why GnRH-based therapies and ulipristal acetate shrink some fibroids and not others depending on mutation status.

Why HMB happens. Submucosal and cavity-distorting fibroids increase endometrial surface area, deform the endometrial-myometrial junction, and produce local TGF-β3 that disrupts BMP-2-mediated endometrial hemostasis. The result: prolonged, heavy, often clot-laden menses that anatomy-blind hormonal therapy can only partly suppress (ACOG 2021).

evidence

Diagnosis. Transvaginal ultrasound is first-line, with reported sensitivity of ~90–99% for any fibroid and ~90% sensitivity/98% specificity for submucosal disease; saline-infusion sonohysterography achieves 98–100% sensitivity/specificity for distinguishing FIGO types 0/1/2 and is cheaper than hysteroscopy. MRI is the most accurate modality for mapping fibroid number, size, and location and is reserved for surgical planning, an enlarged uterus that escapes the ultrasound field, or before uterine artery embolization to confirm vascular supply (Munro et al. 2018) (ACOG 2021).

FIGO classification (Munro 2011, revised 2018). Types 0–2 are submucosal (intracavitary to ≥50% intramural with cavity projection); 3–4 are intramural; 5–7 are subserosal; 8 is "other" (cervical, parasitic, broad ligament). Type 3 abuts the endometrium without invading the cavity; type 7 is pedunculated outside the uterus. Hybrid descriptors (e.g., "2–5") capture transmural lesions. The classification is treatment-determining: submucosal disease drives bleeding and is best resected hysteroscopically; subserosal disease drives bulk and is the easier target for embolization or laparoscopic myomectomy (Munro et al. 2018).

Medical therapies for HMB. Multiple modalities have RCT support, with effect sizes that depend on whether bleeding is the dominant complaint:

• Tranexamic acid (1.3 g three times daily, days of heaviest flow): non-hormonal antifibrinolytic; reduces menstrual blood loss by ~30–50% in HMB generally; ACOG-endorsed first-line for fibroid-related HMB (ACOG 2021).
• LNG-IUS (52-mg levonorgestrel IUD): substantially reduces HMB and improves quality of life in fibroid patients with non-distorted cavities; does not shrink fibroids; expulsion rates are higher than in non-fibroid users (~10–20% in some series) (ACOG 2021).
• Combined oral contraceptives: modest bleeding reduction; do not stimulate fibroid growth at typical doses despite earlier concern.
• Oral GnRH antagonists with hormonal add-back: relugolix+E2+NETA met the <80 mL/>50% reduction primary endpoint in 73% (LIBERTY 1) and 71% (LIBERTY 2) of women vs. ~19% on placebo, with preserved bone mineral density at 24 weeks (Al-Hendy et al. 2021). Elagolix+add-back showed comparable response rates (68.5% UF-1, 76.5% UF-2 vs. ~9% placebo) (Schlaff et al. 2020). Linzagolix with add-back replicated this in PRIMROSE 1 and 2 (Simon et al. 2022). All three are now approved (relugolix combo as Myfembree/Ryeqo; elagolix combo as Oriahnn; linzagolix as Yselty in EU) for symptomatic fibroids in premenopausal women.
• GnRH agonists (leuprolide): pre-surgical use shrinks fibroid volume ~35–60% and corrects anemia over 3–6 months; vasomotor side effects and bone loss limit duration to ~6 months without add-back.

Procedural and surgical interventions.

• Hysteroscopic myomectomy for FIGO 0/1/2 — gold standard for cavity-distorting bleeding fibroids; outpatient, no abdominal incision; effect on HMB durable in 70–80% at 5 years.
• Laparoscopic/robotic or abdominal myomectomy for symptomatic intramural/subserosal disease in uterus-sparing patients. The FEMME trial (n=254, UK) randomized symptomatic uterus-preserving patients to myomectomy vs. uterine artery embolization (UAE); at 2 years UFS-QOL improvement was 8.0 points greater with myomectomy (95% CI 1.8–14.1) (Manyonda et al. 2020). New fibroids develop in 15–30% over 5 years; pregnancy is possible but typically requires cesarean delivery for uterine integrity concerns.
• Uterine artery embolization — interventional radiology procedure infarcting fibroid blood supply; shorter hospital stay (median 2 vs. 5 days), faster return to activity, comparable quality-of-life gains over the long term. The EMMY trial (UAE vs. hysterectomy, n=177) followed patients 10 years: two-thirds of UAE patients avoided hysterectomy, with comparable health-related quality of life at decade (de Bruijn et al. 2016). Reintervention rates are higher than after myomectomy (~15–30% over 5–10 years).
• Hysterectomy — definitive: zero recurrence, no fibroids ever again. Fibroids are the leading indication for hysterectomy in the US, accounting for ~40% of the procedures (ACOG 2021). Removes pregnancy option permanently.
• Radiofrequency ablation (Acessa, Sonata) and MR-guided focused ultrasound (MRgFUS) — newer uterus-sparing thermal ablation options; shorter-term data than myomectomy/UAE; uterine integrity for future pregnancy not as well-established.

protocol

ACOG 2021 management is decision-tree shaped by location, symptom phenotype, and reproductive intent. For HMB without bulk symptoms: trial tranexamic acid (1.3 g po three times daily during menses, up to 5 days/cycle for 6 cycles) and/or LNG-IUS first; escalate to a GnRH antagonist combo if bleeding remains uncontrolled or anemia persists. For submucosal disease with HMB: hysteroscopic myomectomy. For bulky disease with bulk symptoms in a patient who wants her uterus: myomectomy (preferred if fertility is desired) or UAE (if not). For a patient finished with childbearing and refractory to medical therapy: hysterectomy is the most durable answer. GnRH agonists are commonly used for 2–3 months before myomectomy or hysterectomy to shrink fibroid volume and correct anemia preoperatively (ACOG 2021).

fertility / pregnancy (under audience + stakes)

Fertility. The clean signal in the literature is that submucosal fibroids of any size and intramural fibroids that distort the cavity reduce implantation, clinical pregnancy, and ongoing pregnancy rates in ART; hysteroscopic resection of submucosal fibroids roughly doubles clinical pregnancy rates (RR 2.03, 95% CI 1.08–3.82) (Pritts et al. 2009). Non-cavity-distorting intramural fibroids >4 cm have a smaller but probably real negative effect; subserosal fibroids do not appear to affect fertility. ASRM 2017 guidance: hysteroscopic myomectomy for cavity-distorting submucosal fibroids improves clinical pregnancy rates; myomectomy may be considered for asymptomatic cavity-distorting fibroids in patients optimizing for pregnancy. Evidence for impact on live birth and miscarriage rates after myomectomy is weaker (ASRM 2017).

Pregnancy. A 2024 meta-analysis (24 studies, n=237,509) found fibroids raise risk of preterm birth, cesarean delivery, placenta previa, miscarriage, PPROM, placental abruption, postpartum hemorrhage, fetal malposition, IUFD, low birth weight, breech, and preeclampsia (Li et al. 2024). Most pregnancies with fibroids proceed without complications; risk concentrates in large fibroids, retroplacental location, and multiple fibroids. Fibroid growth during pregnancy is non-linear, greatest in the first 7 weeks. Red degeneration (acute infarction-like pain) is the most common pregnancy-specific complication.

contraindications

GnRH antagonist combinations are contraindicated in pregnancy and breastfeeding, in known/suspected hormone-sensitive cancers, and in osteoporosis. LNG-IUS expulsion risk is elevated when the cavity is distorted by submucosal fibroids; insertion should generally follow imaging confirmation that the cavity is regular. UAE is generally avoided in patients actively pursuing pregnancy (data on subsequent fertility are limited and pregnancy rates appear lower than after myomectomy in the few comparative trials). Power morcellation during minimally invasive surgery carries a small but documented risk of disseminating occult uterine sarcoma; the FDA estimated occult leiomyosarcoma prevalence at ~1/352–1/498 among surgeries for presumed fibroids and now recommends contained morcellation only, with avoidance of morcellation entirely in perimenopausal and postmenopausal women given the rising sarcoma incidence with age (FDA 2020).

misconceptions

Common misconceptions worth correcting: (1) "Fibroids always grow until menopause" — Peddada et al. demonstrated heterogeneous growth, with individual fibroids in the same uterus growing at different rates, and even spontaneous regression in premenopausal women (Peddada et al. 2008); (2) "Fibroids cause cancer" — leiomyomas do not transform into leiomyosarcomas, which are biologically distinct; the morcellation risk is about missed occult sarcoma at the time of surgery, not malignant degeneration (FDA 2020); (3) "Estrogen-containing contraception worsens fibroids" — combined OCPs and patches do not stimulate growth at typical contraceptive doses and are reasonable for HMB control (ACOG 2021); (4) "Hysterectomy is the only real cure" — for women who finish childbearing and want one definitive procedure, this is true, but uterus-sparing options (myomectomy, UAE, ablation) are effective for the symptom problem in most women.

audience

Race. Black women experience clinically significant fibroid disease ~10 years earlier than white women, with larger uteri at presentation and 2–3-fold higher prevalence in incidence-matched analyses (Stewart et al. 2017) (Baird et al. 2003). The SELF study, an ultrasound-based prospective cohort of 1,693 young Black women without prior fibroid diagnosis at baseline, established the natural-history baseline for this population and confirmed the earlier-onset signal independent of healthcare access (Baird et al. 2020). Mechanisms remain incompletely understood (genetics, vitamin D status, endocrine-disrupting hair-product exposures, social determinants of health all implicated).

Age. Symptom incidence peaks in the 30s and 40s. Most fibroids regress symptomatically at menopause; new fibroids essentially never form after menopause. A postmenopausal woman with a new or growing pelvic mass needs sarcoma exclusion, not fibroid management.

Reproductive intent. The single biggest treatment-determining variable beyond fibroid location. Hysterectomy is off the table for patients who want pregnancy; UAE is generally off the table; ablation has thinner pregnancy data; myomectomy (preferentially hysteroscopic if feasible) is the workhorse.

practicalities / cost

Annual US economic burden of fibroids is estimated at $5.9–34.4 billion in direct medical costs plus substantial indirect costs through lost productivity (Soliman et al. 2015). Per-patient procedure costs (2014–2015 USD) range hysterectomy $5,000–$8,000, myomectomy $5,400–$11,800, UAE $5,400–$7,600; total direct costs in the year of intervention range $15,878–$21,603 per patient. Indirect costs (lost work, reduced home productivity) add $2,400–$15,500 per affected woman annually. 60% of symptomatic women report quality-of-life impact severe enough to impair physical activity; 24% report it prevents them from reaching potential at work (Soliman et al. 2015). Insurance coverage in the US is generally good for medically necessary fibroid surgery and embolization; emerging therapies like RFA and MRgFUS coverage varies.

stakes

Untreated symptomatic fibroids drag chronic, often unrecognized morbidity. Heavy bleeding produces iron-deficiency anemia in approximately one-third of HMB patients, with fatigue, exercise intolerance, restless legs, hair shedding, pallor, and cognitive fog — symptoms that women and clinicians both routinely misattribute to "just being tired." Bulk symptoms (urinary frequency from anterior subserosal fibroids, constipation from posterior fibroids, abdominal protrusion from a 14-cm uterus) compound social withdrawal and clothing-fit problems. Long-term, untreated HMB-driven anemia compounds with age and can rarely become life-threatening, requiring transfusion. The high prevalence and low recognition explain why fibroids account for 40% of US hysterectomies — many women only present once disease is advanced enough that uterus-sparing treatment is no longer the easiest call (ACOG 2021).

payoff

Treatment-responsive symptoms — particularly HMB — improve dramatically across modalities. Relugolix combination therapy produced ≥50% bleeding reduction in 71–73% of women within 24 weeks (Al-Hendy et al. 2021), with hemoglobin recovery and meaningful UFS-QOL gains. Hysteroscopic myomectomy resolves HMB in ~70–80% of patients with submucosal disease. UAE and myomectomy approximately double quality-of-life scores at 2 years (Manyonda et al. 2020). After menopause, untreated fibroids typically regress and become asymptomatic; observation is a legitimate strategy for women within a few years of expected menopause whose anemia is manageable.

out-of-scope

Adenomyosis (smooth muscle within the endometrium) is frequently co-existent and confused with fibroids on imaging; its management overlaps but is not identical. Endometriosis is a separate entity with separate pathophysiology and treatment despite some symptom overlap. Heavy menstrual bleeding from non-fibroid causes (coagulopathy, ovulatory dysfunction, endometrial polyps, hyperplasia, malignancy — the FIGO PALM-COEIN framework). Sarcoma surveillance after morcellation. Hormone replacement therapy in postmenopausal women with prior fibroids (generally safe; fibroids do not typically regrow on standard HRT doses).

Credibility range

Optimist case

Modern fibroid medicine is a success story. A single condition that 25 years ago meant either hysterectomy or untreated misery now has a layered menu: non-hormonal tranexamic acid for the bleeding-only case, an oral once-daily GnRH antagonist combination with phase 3 RCT evidence for the medically managed case (Al-Hendy et al. 2021) (Schlaff et al. 2020), hysteroscopic resection for the submucosal case, embolization for the uterus-sparing bulky case with a decade of follow-up showing two-thirds of patients avoiding hysterectomy (de Bruijn et al. 2016), and hysterectomy as a definitive option that genuinely cures. FIGO classification gives clinicians a shared language. ACOG 2021 guidance is current and concrete (ACOG 2021). Even imaging is good: TVUS is accurate, sonohysterography reaches near-perfect discrimination of submucosal disease, MRI maps anatomy for surgical planning. The literature is large, the trials are real, and the patient-priority-matched decision tree works.

Skeptic case

Reality is messier. Hysterectomy still accounts for the plurality of fibroid treatments in the US, suggesting the uterus-sparing menu doesn't reach everyone, especially in disadvantaged populations. Racial disparities are enormous and not just biological — Black women present later, with larger fibroids, and receive hysterectomy disproportionately even after adjustment for disease severity. Long-term safety data on GnRH antagonist combinations is still only 1–2 years; bone density worries linger. Ulipristal acetate, briefly the great hope for non-surgical management, was effectively withdrawn over hepatotoxicity. Reintervention rates after UAE are non-trivial (15–30% over 5–10 years). The fertility-after-myomectomy literature is dominated by small observational studies. The leiomyosarcoma morcellation episode reshaped surgical practice for what may be a fairly rare event but a devastating one when missed. And the underlying biology — why some fibroids stay tiny and asymptomatic while others grow to fill the pelvis — remains poorly predictive at the individual level.

Author's call

This entry treats fibroids as a real, common, manageable condition rather than as an inevitable nuisance of being female. The bleeding phenotype is the most important to recognize because it drives anemia that nearly everyone normalizes and almost no one likes; the modern medical menu (LNG-IUS, tranexamic acid, GnRH antagonist combos) is good and underused. Bulk-symptom disease is where the surgical/interventional menu matters most; the right answer depends almost entirely on reproductive intent and fibroid location, which means a thoughtful initial workup with imaging — and a clinician who reads it — is the highest-leverage step. Controversy on individual approaches (UAE vs. myomectomy, when to use morcellation) is real but second-order; the bigger gap is awareness and access, not technology.

Stakeholder and incentive map

• Gynecologic surgeons push toward myomectomy and hysterectomy — the traditional bread-and-butter procedures with the best long-term outcome data and the highest reimbursement.
• Interventional radiologists push UAE, with a competitive ecosystem around UFE marketing; the FEMME trial complicated their pitch but the EMMY 10-year data supports it as a hysterectomy-avoidance tool.
• Device manufacturers (Acessa/Hologic for RFA, InSightec for MRgFUS) push uterus-sparing thermal ablation; trial data is real but shorter-horizon than the surgical alternatives.
• Pharmaceutical industry — Myovant/Pfizer (relugolix combo), AbbVie (elagolix combo), Theramex (linzagolix) drove the GnRH antagonist combo wave with phase 3 trials. All approved drugs are off-patent expensive ($800–$1,000+/month in the US without insurance).
• Patient advocacy — White Dress Project, USA Fibroid Centers, and Black-women-focused organizations have raised awareness of disparities and demanded earlier access to uterus-sparing care.
• Regulators — FDA's 2014 power morcellator warning reshaped the surgical landscape; ACOG's 2021 bulletin codified the medical-then-surgical framework (ACOG 2021).

Population variability

• Race. Black women: earlier onset (~10 years), larger uteri, more multiple fibroids, more symptoms, higher hysterectomy rate, lower uterus-sparing surgery rate (Baird et al. 2003) (Baird et al. 2020).
• Family history. First-degree relative with fibroids approximately doubles risk; HLRCC syndrome (germline FH mutation) presents with multiple early-onset fibroids and renal cell carcinoma risk and warrants genetic counseling.
• Parity. Each term pregnancy after age 25 reduces risk; nulliparity is associated with higher prevalence.
• Obesity and metabolic syndrome. Higher BMI and insulin resistance associated with fibroid risk, plausibly via increased aromatization of androgens to estrogens in adipose tissue.
• Vitamin D. Deficiency associated with higher prevalence in observational data; small RCTs of supplementation showed modest fibroid-volume effects. Mechanistic plausibility (vitamin D inhibits leiomyoma cell proliferation) supports the association but causal evidence is thin.
• Alcohol. Beer specifically associated with higher fibroid risk in cohort data; caffeine not consistently associated.
• Reproductive stage. Premenopausal women are the at-risk population; pregnancy growth is biphasic (rapid early, slower later); menopause produces gradual regression in white women, slower in Black women.

Knowledge gaps

• Why some fibroids stay 1 cm asymptomatic and others reach 15 cm symptomatic remains poorly predictable from genotype, hormones, or imaging at presentation.
• Long-term (5+ year) safety of GnRH antagonist combos is still being characterized, particularly for bone density and cardiovascular endpoints.
• The fertility-and-pregnancy outcomes after UAE, RFA, and MRgFUS are not well-characterized in RCTs; clinical practice errs toward myomectomy when pregnancy is the immediate goal, but the data gap is real.
• Whether earlier intervention in mildly symptomatic Black women (the highest-burden group) would meaningfully reduce eventual hysterectomy rates is the single most important practical question and has no RCT answer.
• Non-hormonal, oral, fibroid-shrinking drugs without GnRH-axis suppression remain an unmet need; the failure of ulipristal acetate left the field without a clean SPRM option.
• Dietary and environmental risk modification (vitamin D, EDCs, weight) is supported by observational signal and biological plausibility but lacks intervention-trial evidence on incidence prevention.

Scoping calls

The brief named bleeding, pelvic pressure, fertility, and pregnancy outcomes as consequences, plus management variation by location and patient priorities. The article covers all four consequences (bleeding in evidence, protocol, stakes; pressure in stakes, protocol; fertility and pregnancy in audience) and frames the management menu around the location-and-priorities axis explicitly in protocol. No silent narrowing.

The audience addressing section does double duty — pregnancy/fertility and Black-women-specific disease. Both are audience-scoped content; combining them avoided two near-duplicate sections and let the disparities story sit alongside the fertility decision tree where it actually lives in clinical practice. Worth flagging because if the disparities content grows in future revisions it may justify its own ad-hoc section.

Rating difficulties

• Beauty dimensions (1/1). Genuinely indirect — visible abdominal protrusion from bulky disease and anemia-driven pallor/hair changes are real but secondary to the underlying bleeding/bulk phenotype. Rated low rather than zero because the visible-belly complaint is common enough in symptomatic cases to count. Did not go higher because it's not what brings most women in.
• Longevity (1). Fibroids are not directly lethal. The 1 captures rare deaths from severe anemia or from morcellation of an occult sarcoma. A 0 would have understated the morcellation issue; anything above 1 would have overstated the actual mortality signal.
• Energy/focus/sleep/mood. All scored through the iron-deficiency-anemia and HMB-quality-of-life pathway. Energy got a 3 because the felt-fatigue effect of HMB-driven anemia is large and routinely under-recognized. Focus, sleep, mood are lower because the effects are real but more diffuse and the literature is downstream (iron repletion → cognition, RLS, etc.) rather than direct fibroid → outcome.
• Evidence (5). The fibroid literature is genuinely Cochrane-level for medical and procedural management — LIBERTY 1/2, Elaris UF-1/2, PRIMROSE 1/2, FEMME, EMMY, plus current ACOG and ASRM guidelines. The 5 is defensible even by the spec's "name 2+ rigorous trials" bar.
• Controversy (2). Lower than it might feel from inside the field — there is broad consensus on diagnosis, on the medical-then-surgical ladder, on hysterectomy as definitive. The active debates (UAE vs. myomectomy ranking, morcellation, racial disparity in treatment selection) are real but not paradigm-level.

Excluded topics — and why

• Sarcoma surveillance after morcellation. Addressed briefly in failure-modes and misconceptions; the deeper postoperative-surveillance workflow is its own topic and warrants a separate entry.
• Detailed surgical technique comparisons (robotic vs. straight-laparoscopic myomectomy, single-port approaches). Beyond what a non-clinician reader needs; the location-and-priorities framework is the right altitude.
• Mifepristone, ulipristal acetate, and other SPRMs. Ulipristal was effectively withdrawn over hepatotoxicity; mifepristone is off-label and not in mainstream US practice for fibroids. Mentioned in research dossier credibility range but not in article body, which would have confused the current-options story.
• Endocrine-disrupting chemicals and hair products. Real signal in the disparities literature but actively researched without intervention-trial evidence; would have stretched the article into prevention territory the body doesn't otherwise cover.
• Vitamin D supplementation as prevention/treatment. Observational signal plus mechanistic plausibility plus thin RCT data on volume reduction. Mentioned in research dossier knowledge gaps; held out of the article because "take vitamin D for your fibroids" overstates the evidence.

Future-link candidates

• heavy-menstrual-bleeding — sibling entry that this one repeatedly forward-references; should land in the same wave.
• iron-deficiency-anemia — the downstream consequence that ties the energy/focus/mood scores together.
• endometriosis, adenomyosis — frequently co-existent, frequently confused, separate management.
• hysterectomy — the procedure itself as a decision (oophorectomy or not, vaginal vs. abdominal vs. laparoscopic) deserves a separate entry given how many entries will link to it.
• menopause-hormone-therapy — needed for the "after menopause, what about HRT?" question this entry deliberately leaves to out-of-scope.

Separate-entry candidates

• Uterine artery embolization — interventional-radiology procedures cut across several gynecology topics (fibroids, adenomyosis, postpartum hemorrhage) and arguably deserve their own entry once those exist.
• Power morcellation and occult sarcoma — touched here but the FDA history, contained-morcellation technique, and the surgical-decision impact are a story big enough to break out.